Is rheumatoid arthritis an infectious disease?
An epidemic would answer the question Unlike most common chronic diseases, little is known about the aetiology of rheumatoid arthritis. Given the concordance rate in monozygotic (identical) twins, any genetic component is unlikely to be greater than 30%,' 2 and no obvious environmental factors exist to explain the remaining 70%. A viral cause seems the most likely. Infections with viruses, such as parvovirus,3 result in inflammatory polyarthritides indistinguishable from rheumatoid arthritis, but seroepidemiological and other studies have failed to confirm a role for parvovirus or, indeed, other viruses in series of patients with rheumatoid arthritis.4"6 The identification of Borrelia burgdorferi as the causative agent for Lyme disease,7 which was initially considered to be an epidemic form of juvenile rheumatoid arthritis, accelerated the search for a microbiological cause for adult rheumatoid arthritis.
Unlike Lyme arthritis, no clusters of rheumatoid arthritis have been reported. Indeed, in familial clusters-in which a shared environmental insult might be expected to play a part -the calendar year of onset of disease in affected sibling pairs agreed no more often than in pairs of sporadic cases.9' No geographically defined populations exist with an exceptionally high incidence of the disease. Rheumatoid arthritis is rare in rural dwelling South African black people"'3 compared with urban dwellers.'4 Urbanisation, being a proxy for overcrowding and perhaps for greater exposure to infectious diseases, may therefore be a risk factor.
The most striking observation about the geographic distribution of rheumatoid arthritis, however, is the similar prevalences reported in many different populations despite the diverse methods used.'5 Few organisms, with the notable exception of Epstein-Barr virus, are sufficiently ubiquitous to explain this geographic pattern. Possibly relevant is the similar geographic distributions of rheumatoid arthritis and infectious mononucleosis. 16 A potentially more rewarding line of inquiry has been the search for time trends in a population. The evidence suggests that rheumatoid arthritis has been declining in both incidence and severity.'7 ' 1 Thus population based studies of cases in both the United States'920 and the United Kingdom2"22 support a decline in incidence in the past 25 years, mirroring the anecdotal impression of rheumatologists.23 Similarly anecdotal evidence exists for a decline in severity-for example, as judged by the occurrence of vasculitis24-though data are limited. Successive generations of patients with rheumatoid arthritis seem increasingly less likely to be positive for rheumatoid factor or to have erosive disease or subcutaneous nodules.25 Mortality, particularly in older women, may be declining,26 though whether this reflects trends in incidence, severity, or certifying death is unclear. More persuasive is the direct observation that follow up of similarly composed groups of patients has shown a fall in the rate of those progressing to severe handicap over the past 25 years.2327 These observations are obviously compatible with several explanations. The decline in severity could be explained by more effective treatment, although limited evidence exists for any of the currently available treatments improving the long term prognosis sufficiently to have an impact on populations. The apparent decline in incidence could be due to changes in diagnostic practice with the application of more rigid criteria. Such a phenomenon, however, would not be consistent with any decline in severity.
Twenty years ago it was postulated that the improvement in atmospheric pollution, perhaps mediated by a reduction in the incidence of respiratory infections, was responsible for the reduction in the prevalence of rheumatoid factor in the population. 28 Others have argued more recently that the temporal patterns ofrheumatoid arthritis are consistent with a similar cyclic change in the epidemicity and virulence of specific, but as yet unknown, micro-organisms.24 29 The conclusion remains that a viral cause for rheumatoid arthritis in genetically susceptible people is the strongest candidate. In the absence of further leads from the laboratory all epidemiologists can do is wait with their bags packed for the call to investigate an apparent epidemic. ALAN Evaluating the effects of second line drugs in a disease that is subject to relapses and remissions is difficult especially when they provide symptomatic relief and have uncertain effects on the underlying disease process. Rheumatologists use measures of disease process and outcome to evaluate the effects of second line drugs'": measures of process consist of variables such as the erythrocyte sedimentation rate, C reactive protein concentration, and titres of rheumatoid factor; measures of outcome encompass various functional indices (for example, the health assessment questionnaire") and radiological progression of joint damage. An important problem with these two modes of measurement is the generally poor correlation between them. Other problems are that most clinical trials monitor changes over one to two years-a relatively short time in the lifetime of the diseaseand the high drop out rate of patients being maintained with second line treatment-less than one third will still be taking their drugs two years on. 12 Many published trials of second line treatment in rheumatoid arthritis have too few patients to be meaningful, a problem that can be overcome by meta-analysis. Using this approach, Clark and her colleagues have shown that over six months injectable gold improved the active joint count, functional capacity, and erythrocyte sedimentation rate by 13-30%. '3 The most common side effect was dermatitis (15%); proteinuria occurred in only 0 7%. Using a similar approach, Iannuzzi et al concluded that in 17 trials suitable for analysis only injectable gold and cyclophosphamide convincingly retarded radiological progression of disease. '1 More recent data, however, suggest that sulphasalazine may also slow the appearance of new joint erosions.'5 Using meta-analysis, Felson et al compared the efficacy and toxicity of six second line drugs and concluded that, apart from auranofin and antimalarials, which had a weaker effect, no significant difference existed between the efficacies of sodium aurothiomalate, penicillamine, methotrexate, and sulphasalazine.'6 (Sodium aurothiomalate, however, was more toxic.) Overall, nearly one in three patients had dropped out of the trials analysed. The authors commented that at least 170 patients are required in each treatment group to give sufficient power to differentiate one second line drug from another.
What about newer treatments? Cyclosporin A has been fashionable, but an 18 month follow up study of 16 patients found that long term loss of renal function occurred and radiological progression was not halted. 17 A recent symposium in the United States challenged the traditional therapeutic "pyramid" in rheumatoid arthritis (a base beginning with non-steroidal anti-inflammatory drugs and progressing through second line drugs to cytotoxic agents at the apex), with several participants advocating the relatively early use of combination treatment with methotrexate, gold, azathioprine, and cyclophosphamide in various permutations.'8 The cost: benefit ratio of such an approach, however, may be high, and so far too few patients have been treated to establish whether combination treatment is better than the pyramid regimen. Immunotherapy with monoclonal antibodies to T cell subsets and the use of cytokine inhibitors may be an advance,'9 but carefully designed trials with sufficient numbers of patients, clearly defined end points, and reasonably long treatment will be required if we are to avoid the pitfalls of the past two decades of antirheumatoid treatment.
